Study of bTAE-HAIC with Lenvatinib and Camrelizumab for Adults Aged 18-75 with Large Intermediate to Advanced Hepatocellular Carcinoma

What this Trial Is About

Researchers are evaluating a combination treatment involving blank-microsphere transcatheter arterial embolization and hepatic arterial infusion chemotherapy bTAE-HAIC with the drugs oxaliplatin, 5-fluorouracil, and leucovorin, along with Lenvatinib and Camrelizumab for patients who have intermediate to advanced large hepatocellular carcinoma liver cancer. This prospective, single-arm study aims to assess the safety and effectiveness of this combined approach, as previous studies have shown individual treatments to be effective but not in this combination. The treatment involves a procedure where a microcatheter is inserted into the artery feeding the tumor, and blank microspheres are delivered based on the tumors blood supply. After this, chemotherapy drugs are infused directly into the hepatic artery every four weeks. Alongside this, patients receive daily oral Lenvatinib and intravenous Camrelizumab every two weeks. The study focuses on this combination therapy without a comparison group. Participants will be monitored over six months to measure the objective response rate to the treatment. Assessments include clinical evaluations and laboratory tests to monitor liver function, blood counts, and other safety markers. Researchers will also track progression-free survival and other outcomes. The study lasts until December 2025, with careful safety monitoring throughout to evaluate the treatments effects on tumor response and patient health.

bTAE-HAIC Combined With System Therapy for Intermediate-advanced Huge HCC